Regulus Therapeutics Inc.
RGLS
Classement en actions
#17335
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Prix de l'action
$8.16
Dernière synchronisation: 2025-06-26
Capitalisation boursière
$234.57M
Changement (1 jour)
0.00%
Changement (1 an)
-56.96%
Pays
US
Échange Regulus Therapeutics Inc. (RGLS)
Catégorie
Healthcare
Revenus pour Regulus Therapeutics Inc. (RGLS)
Revenus en Mar 2024 TTM : $219.60M
Selon les derniers rapports financiers de Regulus Therapeutics Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $219.60M. En 2022, l'entreprise a réalisé un chiffre d'affaires de $298.49M une augmentation par rapport à le chiffre d'affaires de l'année 2021, qui était de $204.23M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Regulus Therapeutics Inc. de 2002 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $219.60M | -16.63% |
| 2023 | $263.41M | -11.75% |
| 2022 | $298.49M | 46.15% |
| 2021 | $204.23M | -48.83% |
| 2020 | $399.10M | 395.72% |
| 2019 | $80.51M | -8.35% |
| 2018 | $87.84M | 9.61% |
| 2017 | $80.14M | 53.12% |
| 2016 | $52.34M | -54.62% |
| 2015 | $115.34M | 49.00% |
| 2014 | $77.41M | -27.79% |
| 2013 | $107.21M | 56.55% |
| 2012 | $68.48M | -47.51% |
| 2011 | $130.46M | 12.11% |
| 2010 | $116.37M | 0.16% |
| 2009 | $116.18M | 16.36% |
| 2008 | $99.85M | 10.24% |
| 2007 | $90.57M | 29.80% |
| 2006 | $69.78M | 640.17% |
| 2005 | $9.43M | -68.37% |
| 2004 | $29.80M | 54.60% |
| 2003 | $19.28M | 9.63% |
| 2002 | $17.58M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 5,648.72% |
US
|
|
| $2.23B | 914.56% |
US
|
|
| $15.74B | 7,069.48% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 2,641.91% |
NL
|
